- 41 次围观
产品图片
货号/SKU
NR-36747
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-36747?? Fluzone? Influenza Virus Vaccine, 2011-2012 Formula(Vaccines)|Influenza A & B viruses|Fluzone? Influenza Virus Vaccine, 2011-2012 Formula|2°C to 8°C|NIAID/NIHAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Fluzone? Influenza Virus Vaccine, 2011-2012 Formula, NR-36747."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
NR-36747 is a split-virus vaccine prepared from influenza viruses A/California/07/2009 X-179A (H1N1)pdm09, A/Victoria/210/2009 X-187 (an A/Perth/16/2009-like virus) (H3N2) and B/Brisbane/60/2008 that were predicted to circulate in the United States during the 2011 to 2012 influenza season.
NR-36747 was prepared from the allantoic fluid of embryonated chicken eggs. The fluid containing the virus was harvested and the virus inactivated with formaldehyde. The inactivated virus was concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus was then chemically disrupted using a nonionic surfactant (Triton? X-100) producing a split-virus. The split-virus was further purified by chemical means and suspended in sodium phosphate-buffered isotonic sodium chloride solution. Gelatin 0.05% was added as a stabilizer.
The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.5 mL syringe contains the recommended ratio of 15 ?g each of the hemagglutinin antigens from influenza viruses A/California/07/2009 X-179A (H1N1)pdm09, A/Victoria/210/2009 X-187 (an A/Perth/16/2009-like virus) (H3N2) and B/Brisbane/60/2008. Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2011-2012 season are now past their expiration dates.
Each syringe contains 0.5 mL of split-virus vaccine in sodium phosphate-buffered isotonic sodium chloride solution containing 0.05% gelatin. The product was formulated without preservatives.
NR-36747 is a split-virus vaccine prepared from influenza viruses A/California/07/2009 X-179A (H1N1)pdm09, A/Victoria/210/2009 X-187 (an A/Perth/16/2009-like virus) (H3N2) and B/Brisbane/60/2008 that were predicted to circulate in the United States during the 2011 to 2012 influenza season.
NR-36747 was prepared from the allantoic fluid of embryonated chicken eggs. The fluid containing the virus was harvested and the virus inactivated with formaldehyde. The inactivated virus was concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus was then chemically disrupted using a nonionic surfactant (Triton? X-100) producing a split-virus. The split-virus was further purified by chemical means and suspended in sodium phosphate-buffered isotonic sodium chloride solution. Gelatin 0.05% was added as a stabilizer.
The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.5 mL syringe contains the recommended ratio of 15 ?g each of the hemagglutinin antigens from influenza viruses A/California/07/2009 X-179A (H1N1)pdm09, A/Victoria/210/2009 X-187 (an A/Perth/16/2009-like virus) (H3N2) and B/Brisbane/60/2008. Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2011-2012 season are now past their expiration dates.
Each syringe contains 0.5 mL of split-virus vaccine in sodium phosphate-buffered isotonic sodium chloride solution containing 0.05% gelatin. The product was formulated without preservatives.
主要内容
此项目的每个订单数量限制为1.此项目每年可订购两次.通过此限制的订单将在发货前发送到NIAID进行批准. NR-36747是由流感病毒制备的分裂病毒疫苗A / CALIFORNIA / 07/2009 X-179a（H1N1） PDM09，A / Victoria / 210/2009 X-187（A / Perth / 16/2009年类似病毒）（H3N2）和B / Brisbane / 60/2008预计在2011年至2012年期间在美国传播流感季节. NR-36747是由胚胎鸡蛋的喉头液体制备的.收获含有病毒的液体，用甲醛灭活病毒.使用连续流动离心机浓缩灭活病毒并在线性蔗糖密度梯度溶液中纯化.然后使用非离子表面活性剂（Triton ? x-100）化学破坏病毒，其产生分裂病毒.通过化学方法进一步纯化分裂病毒并悬浮在磷酸钠缓冲的等渗氯化钠溶液中.加入明胶0.05％作为稳定剂加入. 根据美国公共卫生服务要求标准化血凝素含量.每个0.5mL注射器含有来自流感病毒的血凝素抗原的推荐比例A / CALIFORNIA / 07/2009 X-179A（H1N1）PDM09，A / Victoria / 210/2009 X-187（A / PORTH / 16/2009样病毒）（H3N2）和B / Brisbane / 60/2008. 请注意，该疫苗准备正在释放，仅供参考使用而不是人类使用. 2011-2012赛季生产的疫苗现在已经过到期日期. 每种注射器含有0.5ml含有0.05％明胶的磷酸盐缓冲等渗氯化钠溶液中的0.5ml分裂病毒疫苗.制剂不含防腐剂.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2022-04-01
2021-10-31
2023-12-27
2024-06-14
2022-03-22
2022-08-11
2022-04-01
2022-06-17
2022-04-01
2022-04-01
2022-04-01
2022-04-01
2021-12-21
2023-10-11
2022-04-01